Form 4: Teva Legal Officer's Equity Transactions

Teva Pharmaceutical Industries' Interim Chief Legal Officer, Brian Savage, reported the vesting of restricted share units, subsequent share acquisitions, and sales to cover tax obligations.

Summary

• Brian Savage, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., reported multiple equity transactions on March 4, 2026.
• These transactions included the vesting of Restricted Share Units (RSUs) and the subsequent acquisition of ordinary shares.
• A total of 4,744 ordinary shares were acquired from RSUs granted on March 4, 2022, which vested on March 4, 2026.
• An additional 3,766 ordinary shares were acquired from RSUs granted on March 4, 2024, which also vested on March 4, 2026.
• A new grant of 11,280 Restricted Share Units was awarded on March 4, 2026, with vesting scheduled annually from March 4, 2027, to March 4, 2030.
• To cover tax withholding obligations related to the RSU vestings, Savage disposed of 1,489 ordinary shares and 1,186 ordinary shares, totaling 2,675 shares.
• The shares sold for tax purposes had a weighted average price of $32.4645, with individual transactions ranging from $32.095 to $33.30.
• Following these transactions, Savage's direct beneficial ownership of ordinary shares is 8,461, and he holds 11,280 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting and new RSU grant reflect ongoing executive compensation, while the tax-related sales are a common occurrence and not indicative of a negative outlook.

Positives

• The vesting of Restricted Share Units (RSUs) indicates the fulfillment of long-term incentive compensation for the Interim Chief Legal Officer.
• A new grant of 11,280 Restricted Share Units on March 4, 2026, demonstrates continued long-term incentive alignment between the officer and the company's performance.

Negatives

• The sale of 2,675 ordinary shares to cover tax withholding obligations, while common, represents a reduction in direct share ownership.

Future Outlook

The new grant of 11,280 Restricted Share Units to Brian Savage, vesting annually from March 4, 2027, to March 4, 2030, indicates a continued long-term incentive structure for the Interim Chief Legal Officer.

Industry Context

StockSavvy.ai notes that insider transaction filings like this Form 4 are routine disclosures required by the SEC. While specific to an individual executive's compensation and tax planning, they provide transparency into management's equity holdings and compensation structure, which is a standard practice across the pharmaceutical industry for aligning executive interests with shareholder value.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and equity holdings. The sales for tax purposes are a minor dilution but are standard. The new RSU grant aligns executive interests with long-term company performance.

Next Steps

• Future vesting of 3,766 Restricted Share Units on March 4, 2027, and March 4, 2028, from the March 4, 2024 grant.
• Future vesting of 2,820 Restricted Share Units annually from March 4, 2027, to March 4, 2030, from the March 4, 2026 grant.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, including RSU vestings and tax-related share sales, along with a new RSU grant. These transactions are standard and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not present significant positive or negative catalysts for the stock.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Restricted Share Units, RSU, Equity Compensation, Officer Transactions, Brian Savage, Share Vesting, Stock Sale